
    
      Study aim:

      The objective of this proposal is to conduct a pilot clinical trial to determine if the
      mitochondrial-targeted anti-oxidant MitoQ improves airway reactivity in obese patients with
      poorly controlled asthma.

      Type of Study:

      A 14 weeks, prospective, two center (Duke and the University of Vermont), randomized,
      placebo-controlled, double-masked clinical trial.

      Study Population:

      40 patients with obesity and poorly controlled asthma.

      Intervention:

      MitoQ 40 mg per day versus placebo.
    
  